Recent Advances in Optically Controlled PROTAC

Nov 28, 2023·
Muzi Ouyang (Mia)
Muzi Ouyang (Mia)
,
Ying Feng
,
Hui Chen
,
Yanping Liu
,
Chunyan Tan
,
Ying Tan
· 0 min read
DOI
Abstract
Proteolysis-targeting chimera (PROTAC) technology is a groundbreaking therapeutic approach with significant clinical potential for degrading disease-inducing proteins within targeted cells. However, challenges related to insufficient target selectivity raise concerns about PROTAC toxicity toward normal cells. To address this issue, researchers are modifying PROTACs using various approaches to enhance their target specificity. This review highlights innovative optically controlled PROTACs as anti-cancer therapies currently used in clinical practice and explores the challenges associated with their efficacy and safety. The development of optically controlled PROTACs holds the potential to significantly expand the clinical applicability of PROTAC-based technology within the realm of drug discovery.
Type
Publication
Bioengineering, 10(12), 1368
Status
Peer-reviewed Open access
publications
PROTAC Targeted Protein Degradation Photopharmacology
Muzi Ouyang (Mia)
Authors
Muzi Ouyang (Mia)
PhD Candidate

I am Muzi Ouyang (欧阳木子) — I go by Mia. I am a PhD candidate in Chemistry at Tsinghua University, advised by Prof. ADVISOR NAME. My research is on YOUR TOPIC — ONE SENTENCE ON WHAT YOU FOUND OR BUILT.

My background spans animal science, basic medicine and chemistry, so I work comfortably at the interface between them. (Rewrite or delete this line — but a deliberate framing of an interdisciplinary path reads as a strength, whereas leaving it unexplained invites the question.)

I expect to defend in June 2027 and am seeking postdoctoral positions starting in late 2027. If my work overlaps with your group’s, I’d be glad to hear from you — my CV is linked above. Write to me at mumumia.1009@gmail.com, or oymzmia@163.com if you are corresponding from within China.